Last checked at 
(Alliance News) - OptiBiotix Health PLC on Monday said it has signed a licence agreement with Kappa Bioscience AS covering Lactobacillus plantarum LPLDL in cardiovascular health.
The agreement is for a new application area in cardiovascular health and covers 27 countries, predominantly in Europe but also in Russia and Singapore.
The product is to combine probiotic strain LPLDL, which is intended to reduce cholesterol and blood pressure, with Kappa's vitamin K2 product K2VITAL. The goal of the product is to "improve vascular health".
Nutrilinea Srl in Italy will cover development costs and manufacture the final product, with Kapp and OptiBiotix commercialising it.
"This broadens the use of LPLDL beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. The result is a new product for vascular health, a segment of cardiovascular care where very few products are currently available. This increases brand recognition and value in addition to creating a demand for LPLDL as an ingredient. This means we are able to derive revenue from both the sale of a wide range of cardiovascular health products containing LPLDL, as well as LPLDL ingredient sales," said OptiBiotix Business Development Director Luis Gosalbez.
Shares in OptiBiotix were up 1.5% at 85.22 pence in London at midday on Monday.
